Skip to Content

Menveo Approval History

  • FDA approved: Yes (First approved February 19th, 2010)
  • Brand name: Menveo
  • Generic name: meningococcal conjugate vaccine
  • Company: Novartis Vaccines and Diagnostics
  • Treatment for: Meningococcal Meningitis Prophylaxis

Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.

Development History and FDA Approval Process for Menveo

Aug  2, 2013Approval FDA Expands Age Indication for Menveo
Jan 31, 2011Approval FDA Approves the Novartis Quadrivalent Meningococcal Conjugate Vaccine, Menveo, for Use in Children From 2 Years of Age
Feb 22, 2010Approval Novartis Gets US Approval for Menveo Meningitis Vaccine
Jul  1, 2009Novartis Receives Complete Response Letter From The US Food And Drug Administration For Its Investigational Vaccine Menveo

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.